« Return to News | Drug Sponsors

Gilead and J&J explore combo HIV Treatment

Wednesday, June 29, 2011 10:00 AM

Gilead and Johnson & Johnson's Tibotec subsidiary are joining forces on a combo HIV treatment, according to FierceBiotech. Under a new pact, Gilead will combine its new boosting agent cobicistat with J&J's Prezista, a protease inhibitor. This new therapy follows a well-traveled development path as drug companies advance new HIV drugs that require fewer pills and offer greater potency.

Cobicistat—now in phase III testing—is designed to increase the blood levels of HIV drugs, making it an ideal candidate for more combo product deals. Interestingly, the companies also outlined ongoing talks on a separate pact on the development and commercialization of a future single-tablet regimen combining Prezista with Gilead's Emtriva, its experimental GS7340 and cobicistat. Gilead would be responsible for the development and commercialization of the new STR on a worldwide basis.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.